We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 9 augustus 2017

The Lancet: [Articles] Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed...

[Articles] Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
Four cycles of neoadjuvant ECX compared with two cycles of CF did not increase survival, and cannot be considered standard of care. Our study involved a large number of centres and detailed protocol with comprehensive prospective assessment of health-related quality of life in a patient population confined to people with adenocarcinomas of the oesophagus and gastro-oesophageal junction (Siewert types 1 and 2). Alternative chemotherapy regimens and neoadjuvant chemoradiation are being investigated to improve outcomes for patients with oesophageal carcinoma.
Read more

[Articles] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Progression-free survival was longer in patients who received ipatasertib than in those who received placebo. To our knowledge, these are the first results supporting AKT-targeted therapy for triple-negative breast cancer. Ipatasertib warrants further investigation for the treatment of triple-negative breast cancer.
Read more

[Comment] Targeting PI3K/AKT pathway in triple-negative breast cancer
Metastatic triple-negative breast cancer has one of the worst prognoses of all cancers. Its associated median overall survival of only 13 months has not changed for almost two decades despite many efforts to develop alternative approaches to chemotherapy, including targeting angiogenesis, DNA repair, and EGFR.1 Potential explanations are the very heterogeneous and unstable nature of this disease, together with the absence of known leading oncogenic drivers.1,2
Read more

[Corrections] Correction to 2017; 18: e429
The European Low-Grade Glioma Network. Evidenced-based medicine in glioma: molecular biology is only part of the story. Lancet Oncol 2017; 18: e429—The title of this Correspondence should have been "Evidenced-based medicine in glioma: molecular biology is only part of the story" and not "Evidence-based management of adult patients with diffuse glioma". This correction has been made to the online version as of Aug 8, 2017.
Read more

[News] NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma
On August 9, 2017, the National Institute for Health and Care Excellence (NICE) published technology appraisal guidance1 recommending cabozantinib, within its marketing authorisation, as an option for the treatment of advanced renal cell carcinoma in adults after VEGF-targeting therapy, only if the company provides cabozantinib with the discount agreed.
Read more